Indian Emulsifiers, a Mumbai-based specialty chemicals manufacturer, has officially opened its rights issue, providing existing shareholders with an opportunity to increase their stake in the company. The issue, which aims to raise INR 49.50 crore, is scheduled to remain open from 16 November to 1 December 2026. This capital infusion is intended to support the company’s ongoing expansion and working capital requirements as it scales its operations in the specialty chemicals sector.

Rights Issue Structure and Key Dates

The company has set the issue price at INR 27 per share, with a face value of INR 10. Shareholders on the record date of 27 October 2026 are entitled to participate in the offering at a ratio of 1 equity share for every 1 equity share held. The total issuance comprises 1,83,33,222 new equity shares.

Parameter Details
Rights Issue Price INR 27 per share
Issue Size INR 49.50 crore
Entitlement Ratio 1:1
Record Date 27 October 2026
Issue Opening Date 16 November 2026
Issue Closing Date 1 December 2026
Listing Exchange NSE SME

Investors should note that the entire amount of INR 27 per share is payable in full at the time of application. The company has facilitated the renunciation of rights entitlements, allowing shareholders to sell their rights in the market until 25 November 2026 if they choose not to exercise their subscription option.

Business Model and Operational Expansion

Founded in 2020, Indian Emulsifiers has established a significant footprint in the manufacturing of specialty chemicals, including esters, phosphate esters, imidazolines, and sulfosuccinates. These products cater to diverse industries such as food processing, personal care, mining, and oil and gas.

The company currently operates a production facility at MIDC Lote Parshuram, Ratnagiri, which has seen its capacity rise to 12,000 metric tons per annum following the addition of new reactors. Furthermore, a second manufacturing unit is currently under construction at the same industrial location, with operations expected to commence by the end of 2026. This expansion reflects the company’s intent to capture a larger share of the growing demand for specialized chemical agents.

Financial Performance Overview

Financial data highlights a consistent upward trajectory in the company’s top-line and bottom-line figures over the last three fiscal years.

Metric (INR Crore) FY 2024 FY 2025 FY 2026
Revenue 67 101 160
Net Income 9 13 19

The consistent growth in revenue, moving from INR 67 crore in FY 2024 to INR 160 crore in FY 2026, underscores the company’s scalability. Net income has similarly improved, demonstrating the company’s ability to manage costs effectively while expanding its revenue base.

Strategic Deployment of Capital

The funds raised from this rights issue are earmarked for specific growth-oriented activities. The allocation includes:

  • INR 9.6 crore for working capital support in its US subsidiary, Polaris Specialty Chemicals Inc.
  • INR 6 crore for the acquisition of shares in Chemical Brothers Enterprises Pvt Ltd.
  • INR 22.8 crore allocated to meet both existing and incremental working capital requirements.
  • INR 10.6 crore designated for general corporate purposes.

By investing in its US subsidiary and acquiring strategic stake holdings, Indian Emulsifiers is positioning itself to strengthen its global presence and diversify its product integration chain. The management, led by promoter Yash Tikekar, aims to leverage this capital to sustain the company’s momentum in the competitive specialty chemicals market.

Market Analysis and Valuation Context

When assessing the rights issue, investors often look at the dilution factor and the gap between the issue price and the prevailing market price. Based on the market price of INR 62.40 per share at the time of approval, the issue price of INR 27 represents a significant discount. The theoretical fair value post-dilution is calculated to be approximately INR 44.70 per share, based on the reported figures. This price adjustment is a standard result of issuing a large volume of new shares at a premium lower than the current market valuation.

The successful execution of this rights issue will be critical for the company to finalize its second manufacturing unit without over-leveraging its balance sheet. With the listing scheduled for 3 December 2026 on the NSE SME platform, the market will be closely observing the uptake by existing shareholders and the subsequent liquidity profile of the stock.

Key Takeaways

  • The rights issue is open until 1 December 2026, offering a 1:1 entitlement ratio.
  • The company is raising INR 49.50 crore to fund global expansion, working capital, and strategic investments.
  • Financials show strong growth, with revenue increasing from INR 67 crore in FY 2024 to INR 160 crore in FY 2026.
  • Proceeds include INR 9.6 crore for the US-based subsidiary, Polaris Specialty Chemicals Inc.
  • The shares are expected to be listed on the NSE SME platform by 3 December 2026.

Frequently Asked Questions

What is the Indian Emulsifiers Rights Issue Price?

The issue price is INR 27 per share, which includes a premium of INR 17 over the face value of INR 10.

What is the Indian Emulsifiers Rights Issue entitlement ratio?

The eligible shareholders are offered 1 equity share for every 1 equity share held on the record date.

What is the Indian Emulsifiers Rights Issue Record Date?

The Indian Emulsifiers rights issue record date was 27 October 2026.

How can shareholders apply for the rights issue?

Investors can apply through Internet banking using ASBA (Application Supported by Blocked Amount) or through their stock broker using UPI.

What are the primary objectives of the rights issue?

The funds will be used for investment in the US subsidiary Polaris Specialty Chemicals Inc (INR 9.6 crore), acquiring shares of Chemical Brothers Enterprises Pvt Ltd (INR 6 crore), working capital (INR 22.8 crore), and general corporate purposes (INR 10.6 crore).

When will the shares list on the exchange?

The shares are expected to be listed on the NSE SME platform on or about 3 December 2026.

Can I sell my rights entitlement?

Yes, rights entitlements can be sold in the market until the renunciation date, which is 25 November 2026.

What is the total number of shares being offered?

The company is offering 1,83,33,222 shares through this rights issue.